Figure 4.

T17-MnO₂ enhanced the immune response of BMDMs. (A) A schematic diagram of the synthesis of T17-MnO₂. (B, C) Particle size distribution and zeta potential of T17-MnO₂ were detected by the nanoparticle size analyzer. (D) LDH release of BMDMs was detected after T17-MnO₂ treatment for 24 h. After treatment of MnCl₂ (50 μmol/L), MnO₂ (50 μmol/L), T17 (200 nmol/L), T17+MnCl₂, and T17-MnO₂ for 24 h, (E) the mRNA levels of Ifnb in BMDMs were detected by Real-time PCR, (F) the protein level of TBK1 in BMDMs was detected by Western blot, (G–I) and the protein levels of INOS, CD86 and CD206 were detected by flow cytometry. Data are presented as mean ± SD (n = 3). ∗∗P < 0.01, ∗∗∗P < 0.001, ∗∗∗∗P < 0.0001, ns, not significant.